Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

April 6, 2018: By Joan McKenna

The Delaware Supreme Court has ruled in favor of Alcon in a suit brought by Elenza, a Virginia-based medical device company, over an electroactive intraocular lens (EAIOL) for cataract patients.

The court, ruling on an appeal by Elenza, said March 20 that it agreed with Delaware’s Superior Court that Elenza failed to support its claim that Texas-based Alcon improperly used or disclosed any of Elenza’s alleged trade secrets.

From 2008 to 2010, Elenza worked on EAIOL technology that used electric power and changes in eye pupil size to “trigger” focus. Alcon was also exploring EAIOL lenses. The two companies decided to work together.

On May 24, 2010, Elenza and Alcon signed a non-disclosure agreement, followed by a stock purchase agreement that included development milestones.

In December 2011, Alcon decided that Elenza had not met the first milestone, and the companies parted ways in July 2012, though they remained under the contractual obligations of the NDA.

Elenza was unable to find another investor and ceased operations in August 2013.

That same month, Alcon filed a patent application for an electro-active lens that automatically accommodates based on the movements of the eye’s ciliary muscle.

On March 20, 2014, Elenza filed a complaint against Alcon and claimed breach of contract and misappropriation of trade secrets.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ivantis Gains US FDA Approval for Hydrus Microstent

US FDA Approves Sun Pharma’s CEQUA for Dry Eye

Regeneron Receives US FDA Approval for 12-Week Eylea Dosing

STAAR, Japan’s Shinjuku LASIK Clinic Sign Multiyear Agreement

Alcon Launches Finesse Sharkskin ILM Forceps

Imprimis’ Q2-2018 Revenues Increase 51 Percent to $10.4 Million

Bausch Health Revenues in Q2-2018 Drop 5 Percent

TearLab’s Q2-2018 Revenues Drop 8.5 Percent to $6.4 Million

DeepMind AI System Accurately Detects Eye Disease in OCT Scans at Moorfields

Study by MIT, Mass Eye and Ear Suggests Glaucoma is Autoimmune Disease

Study Indicates Insulin May Restore Vision in Glaucoma

CHOP Researchers Define Six ROP Indicators

Nicox Initiates Phase II Study of NCX 470 in Open-Angle Glaucoma, Ocular Hypertension

Eyenovia’s Microdose Latanoprost Delivers Drug with Precision, Lowers IOP in Proof-of-Concept Study

Rayner to Launch Sulcoflex Trifocal Toric IOL in September

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT